Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

NCT00434512 | Completed Phase 2 Results

• 2 other identifiers: 1087062006-003796-12
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.

Conditions

AIDS; HIV Infections

Keywords

Gag; vaccine; adjuvant; HIV; Pol; Nef

Outcome Measures

Primary Outcomes (12)

• Number of Subjects With Any and Grade 3 Solicited Local Symptoms

  Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.

  During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)

• Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

  Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, sweating, gastrointestinal symptoms(nausea, vomiting, diarrhea, and/or abdominal pain). Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  During the 7-day (Days 0-6) follow-up period after each vaccination and overall (across doses)

• Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

  An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  During the 30-day (Days 0-29) follow-up period after vaccination (across doses)

• Number of Subjects With Serious Adverse Events (SAEs) and Related SAEs

  Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  During the whole study period (From Month 0 up to Month 12)

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 0

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 0

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 1

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 1

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Day 44

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Day 44

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 2

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[RBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 2

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 6

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 6

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 9

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 9

• Number of Subjects With Abnormal Haematological and Biochemical Levels at Month 12

  The frequency distribution of values below, within and above normal ranges, were tabulated per treatment group at each scheduled time point for the following biochemical or haematological parameters: red blood cells \[RBC\] count, haemoglobin, haematocrit, white blood cell \[WBC\] count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, sodium, potassium, urea nitrogen, creatinine, alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\].

  At Month 12

• Number of Subjects With a Response in Terms of Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least Two Cytokines Including IL-2 Equal or Above the Cut-off to at Least 1, 2, 3 Antigens and to All 4 Antigens

  Antigen-specific CD4+ T-cells can express cluster of differentiation 40-ligand (CD40-L) and produce the cytokines Interleukin 2 (IL-2) and/or Tumor Necrosis Factor alpha (TNF-α) and/or Interferon-gamma (IFN-γ). The frequency of antigen specific CD4+T-cells was calculated as the difference between the frequency of CD4+T-cells producing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L), upon in vitro stimulation with the peptide pools derived from the antigen minus the frequency of CD4+T-cells producing at least 2 cytokines upon in vitro stimulation in medium only.A responder was a subject with an antigen-stimulated CD4+T cells response greater than or equal to the cut-off value. The same cut-off value was used for all subjects and all antigen responses post-vaccination. It was calculated from the pre-vaccination CD4+T cell responses (the frequency of antigen-stimulated CD4+T cells expressing at least two markers; i.e. all doubles) for all subjects.

  At Day 44

Secondary Outcomes (3)

• Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing IL-2 and at Least Another Marker

  At Month 0, Day 44, Month 2, Month 6 and Month 12

• Frequency of p17, p24, Nef and RT-specific CD4+ T-cells Expressing at Least 2 Immune Markers

  At Month 0, Day 44, Month 2, Month 6 and Month 12

• Antibody Titers Against p17, p24, Nef, RT and F4co Antigens

  At Month 0, Day 44, Month 2, Month 6 and Month 12

Study Arms (6)

SB732461 adjuvanted_LD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

SB732461 adjuvanted_MD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

SB732461 adjuvanted_HD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

SB732461 non-adjuvanted_LD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose \[LD\] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

SB732461 non-adjuvanted_MD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose \[MD\] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

SB732461 non-adjuvanted_HD Group

EXPERIMENTAL

Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose \[HD\] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.

Biological: HIV vaccine 732461

Interventions

HIV vaccine 732461 BIOLOGICAL

SB732461 adjuvanted_HD Group; SB732461 adjuvanted_LD Group; SB732461 adjuvanted_MD Group; SB732461 non-adjuvanted_HD Group; SB732461 non-adjuvanted_LD Group; SB732461 non-adjuvanted_MD Group

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• A male or female between and including 18-40 years at the time of first vaccination.
• Written informed consent obtained from the subject prior to any study procedure.
• Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
• Good general health without significant medical history, physical examination findings, or clinically significant abnormal laboratory results.
• If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
• Negative for antibodies against HIV-1, HIV-2 and negative for HIV p24 antigen within 56 days (8 weeks) prior to enrolment. Subjects must be willing to accept HIV test results. Individuals who elect not to receive test results will not be enrolled.
• Negative for anti-HBc Ab, HBsAg and anti-HCV Ab.

You may not qualify if:

• Women who are pregnant or breast-feeding.
• Subjects with a history of, or current, alcohol or substance abuse.
• The subject is at high risk of acquiring HIV according to the behavioural risk assessment questionnaire.
• Morbid obesity
• Receipt of live attenuated vaccines within 30 days of enrolment.
• Receipt of medically indicated subunit or killed vaccines or allergy treatment with antigen injections within 14 days of study vaccine administration.
• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Prior receipt of HIV-1 vaccines or placebo in a previous HIV vaccine trial.
• Receipt of blood products 120 days prior to HIV screening.
• Receipt of immunoglobulin 120 days prior to HIV screening.
• History of serious adverse reactions including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema and abdominal pain to vaccines.
• History of serious allergic reaction to any substance requiring hospitalization or emergency medical care.
• History of immunodeficiency or autoimmune disease.
• History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccination.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Ghent, 9000, Belgium

Location

Related Publications (3)

• Leroux-Roels G, Bourguignon P, Willekens J, Janssens M, Clement F, Didierlaurent AM, Fissette L, Roman F, Boutriau D. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine. Clin Vaccine Immunol. 2014 Mar;21(3):302-11. doi: 10.1128/CVI.00617-13. Epub 2014 Jan 3.

  PMID: 24391139 DERIVED

• Van Braeckel E, Koutsoukos M, Bourguignon P, Clement F, McNally L, Leroux-Roels G. Vaccine-induced HIV seropositivity: a problem on the rise. J Clin Virol. 2011 Apr;50(4):334-7. doi: 10.1016/j.jcv.2011.01.003.

  PMID: 21300566 DERIVED

• Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitie MA, Voss G, Leroux-Roels G, McNally L. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160. Epub 2011 Jan 5.

  PMID: 21208909 DERIVED

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome; HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 12, 2007
• First Posted: February 13, 2007
• Study Start: February 20, 2007
• Primary Completion: June 13, 2008
• Study Completion: June 13, 2008
• Last Updated: October 1, 2019
• Results First Posted: October 1, 2019

Record last verified: 2019-09

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD is available via the Clinical Study Data Request site (click on the link provided below).
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Locations

BE (1)